Tarsus Pharmaceuticals, Inc. TARS Amount that if recognized, would affect the effective tax rate or regulatory liability
Amount that if recognized, would affect the effective tax rate or regulatory liability at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s amount that if recognized, would affect the effective tax rate or regulatory liability.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s amount that if recognized, would affect the effective tax rate or regulatory liability?
- Tarsus Pharmaceuticals, Inc. (TARS) reported amount that if recognized, would affect the effective tax rate or regulatory liability of $0 in Q4 2025.